- TrovaGene (TROV -0.1%) says it's partnering with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using itss cell-free DNA assays.
- The study is designed to demonstrate that cell-free DNA obtained from urine is a viable systemic sample for colorectal cancer disease monitoring, which includes measuring therapy response, identifying cancer genomic changes and monitoring disease progression.
Trovagene partners with USC in clinical study of cancer monitoring technology
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs